Analysts Set Teva Pharmaceutical Industries Limited (NYSE:TEVA) Price Target at $23.57

Teva Pharmaceutical Industries Limited (NYSE:TEVA) has earned a consensus rating of “Moderate Buy” from the seven analysts that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $23.57.

TEVA has been the subject of a number of research analyst reports. UBS Group lowered their price target on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating for the company in a report on Thursday, January 30th. Barclays dropped their target price on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a report on Thursday, January 30th. StockNews.com cut shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, December 18th. JPMorgan Chase & Co. increased their price objective on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a research note on Monday, October 21st. Finally, Piper Sandler boosted their target price on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a research note on Friday, January 17th.

Insider Buying and Selling at Teva Pharmaceutical Industries

In related news, EVP Christine Fox sold 19,388 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total value of $327,075.56. Following the transaction, the executive vice president now directly owns 44,104 shares of the company’s stock, valued at $744,034.48. The trade was a 30.54 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Roberto Mignone sold 286,000 shares of the firm’s stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the transaction, the director now owns 695,000 shares of the company’s stock, valued at approximately $15,296,950. The trade was a 29.15 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.55% of the company’s stock.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

Institutional investors and hedge funds have recently modified their holdings of the business. AQR Capital Management LLC acquired a new position in shares of Teva Pharmaceutical Industries during the second quarter valued at about $262,000. Cetera Investment Advisers grew its stake in Teva Pharmaceutical Industries by 83.9% in the second quarter. Cetera Investment Advisers now owns 60,868 shares of the company’s stock valued at $989,000 after acquiring an additional 27,765 shares during the period. Sanctuary Advisors LLC acquired a new stake in Teva Pharmaceutical Industries in the second quarter valued at approximately $560,000. GAMMA Investing LLC increased its holdings in shares of Teva Pharmaceutical Industries by 52.3% during the third quarter. GAMMA Investing LLC now owns 5,161 shares of the company’s stock valued at $93,000 after acquiring an additional 1,773 shares in the last quarter. Finally, Artemis Investment Management LLP bought a new position in shares of Teva Pharmaceutical Industries in the 3rd quarter worth $9,783,000. 54.05% of the stock is currently owned by institutional investors.

Teva Pharmaceutical Industries Stock Performance

TEVA opened at $16.62 on Friday. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.61 and a current ratio of 0.98. Teva Pharmaceutical Industries has a 52-week low of $12.43 and a 52-week high of $22.80. The firm has a market cap of $18.83 billion, a P/E ratio of -11.46, a price-to-earnings-growth ratio of 1.39 and a beta of 0.71. The business’s fifty day moving average is $20.05 and its 200-day moving average is $18.52.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. Sell-side analysts expect that Teva Pharmaceutical Industries will post 2.62 EPS for the current fiscal year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.